share_log

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

HC Wainwright & Co.重申買入Halozyme Therapeutics,維持50美元的目標股價
Benzinga ·  05/08 07:30

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 price target.

HC Wainwright & Co. 分析師米切爾·卡普爾重申Halozyme Therapeutics(納斯達克股票代碼:HALO)的買入並維持50美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論